Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL)
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
This study compares two photosensitizing creams' BF-200 ALA's (aminolevulinic acid, Ameluz®)
and MAL's (methyl 5-aminolevulinate, Metvix®) efficacy on actinic keratoses in natural
daylight photodynamic therapy (NDL-PDT). The participants' facial skin or scalp will be
randomized in two sides and one side is treated with BF-200 ALA and the other side with MAL.
Result of the treatment is assessed with clinical examination 12 months after treatment. The
investigators will also compare delayed skin reactions after treatment and cost-effectiveness
of both photosensitizer creams.
Phase:
Phase 4
Details
Lead Sponsor:
Joint Authority for Päijät-Häme Social and Health Care
Collaborators:
Päijänne Tavastia Central Hospital STUK - Radiation and Nuclear Safety Authority: Finland Tampere University Tampere University Hospital University of Tampere Vaasa Central Hospital, Vaasa, Finland